Praxis Precision Medicines

Recent news

• Rating change
  A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800
  Market Newswire · 2026/8/7
• Rating change
  Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945
  Market Newswire · 2026/8/17
• Rating change
  Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650
  Market Newswire · 2026/8/18
• H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201
  Market Newswire · 2026/10/6
• JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $534
  Market Newswire · 2026/10/2
• Rating change
  A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201
  Market Newswire · 2026/8/8
• Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $582
  Market Newswire · 2026/9/24
• Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575
  Market Newswire · 2026/8/21
• Rating change
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $719
  Market Newswire · 2026/7/22
• Rating change
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754
  Market Newswire · 2026/8/8
• Rating change
  RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $449
  Market Newswire · 2026/7/11
• Rating change
  Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800
  Market Newswire · 2026/6/30
• Rating change
  Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200
  Market Newswire · 2026/7/13
• Rating change
  H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
  TipRanks · 2026/8/7
• Rating change
  Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $575
  Market Newswire · 2026/8/20
• Rating change
  Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $550
  Market Newswire · 2026/6/30
• Company notice
  Praxis Precision Medicines: Praxis Precision Medicines, Inc. - Reverse Split Option Symbol: PRAX New Symbol: PRAX1
  OCC · 2023/11/28
• Rating change
  Jefferies Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $447
  Market Newswire · 2026/7/14
• Rating change
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719
  Market Newswire · 2026/6/30
• Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)
  TipRanks · 2026/10/6

Headlines are aggregated automatically and are not independently verified or edited by our team.